ABSTRACT
To determine the association of Xenotropic murine leukemia virus related virus [XMRV] infection with prostate cancer and compare it with benign prostate hyperplasia. Case control study. Department of Histopathology and Molecular Pathology, Dow University of Health Sciences, Karachi, from January 2009 to December 2012. XMRV was screened in 50 prostate cancer and 50 benign prostatic hyperplasia biopsies using conventional end-point PCR. Other studied variables were family history of prostate cancer, patients age and Gleason score. XMRV was detected in 4 [8%] of the 50 prostate cancer biopsy specimens compared to none in biopsies with benign prostatic hyperplasia. However, there was no significant statistical association of XMRV infection with the other variables. A low frequency of XMRV infection was found in this case-control study. Men, who harbor XMRV infection, may be at increased risk of prostate cancer but this needs to be investigated further at a larger scale
ABSTRACT
Background: A family history of prostate cancer has been associated with increased risk of prostate cancer development, but the risks were inconsistent in terms of the affected family members and the data on prostate cancer characterization with respect to family history of disease among Pakistani men is limited
Objective: To characterize prostate cancer based on family history into familial including hereditary and sporadic cases and to investigate the association with diagnostic modalities; age of patient at diagnosis and pathological tumor grade
Methods: A self-administered written questionnaire was forwarded to 100 patients diagnosed with prostate adenocarcinoma, containing questions about age at diagnosis and cases of prostate cancer in family. The information regarding age of patient at diagnosis, cases of prostate cancer in relative, pathological tumor grade and age at death for all relatives affected by prostate cancer was acquired. The data was validated through the biopsy report of patient and medical records of relative affected by prostate cancer, provided by patient respectively. Patients were then divided into three groups according to their family history: familial prostate cancer [FPC], hereditary prostate cancer [HPC] and sporadic prostate cancer [SPC] groups
Results: 17% of the patients were categorized in the FPC group, of which 2% were identified as having HPC and 81% were assigned SPC group. Overall, there was no significant statistical difference between groups and study variables
Conclusion: We found no difference in age and pathological tumor grade, in patients diagnosed with adenocarcinoma of prostate following TURP. These results are consistent with previous studies except that patients with HPC in previous studies were significantly younger at diagnosis
ABSTRACT
The world populations are classified into slow and fast acetylator phenotypes based on their genetic Lineage. Though some genetic intermixing exists in most populations, trend in genetic phenotypes in randomly mixed populations have not been reported. The population occupying the northwestern part of the Indian subcontinent [now Pakistan] is a unique example of prolonged and random mixing of divergent races. This study reports the genetic phenotyping in this randomly mixed populations and concludes that divergent phenotyes, randomly mixed, yield a perfect 50% distribution of slow and fast acetylators. The metabolic acetylation status in the subject population was studied using Sulfadimidine as the marker at a dose of 3 mg/kg. The pharmacokinetics of Sulfadimidine and its acetylated metabolite were studied. The acetylation of Sulfadimidine was found to be bimodal with equal distribution between rapid and slow acetylators. The pharmacokinetics parameters of sulfadimidine and its acetylated metabolite, except renal clearance, differed significantly between the rapid and slow acetylators